Comparative activity of eight antimicrobial agents against clinical bacterial isolates from the United States, measured by two methods

American Journal of Medicine

Volumn 100, Issue 6 A, 1996, Pages 26S-38S

  Thornsberry, Clyde ^a   Yee, Y Cheung ^a  

^a MRL Pharmaceutical Services   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CEFEPIME; CEFOTAXIME; CEFTAZIDIME; CEFTRIAXONE; CIPROFLOXACIN; GENTAMICIN; IMIPENEM; METICILLIN; PIPERACILLIN; ANTIINFECTIVE AGENT;

ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; BACTERIUM ISOLATION; CITROBACTER FREUNDII; CONFERENCE PAPER; ENTEROBACTER AEROGENES; GRAM NEGATIVE INFECTION; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; SPECIES DIFFERENCE; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS INFECTION; ANTIBIOTIC RESISTANCE; ARTICLE; COMPARATIVE STUDY; DOSE RESPONSE; DRUG ANTAGONISM; DRUG EFFECT; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HUMAN; ISOLATION AND PURIFICATION; METHODOLOGY; MICROBIOLOGICAL EXAMINATION; RANDOMIZATION; STATISTICS; UNITED STATES;

ANTI-BACTERIAL AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, MICROBIAL; GRAM-NEGATIVE BACTERIA; GRAM-POSITIVE BACTERIA; HUMANS; MICROBIAL SENSITIVITY TESTS; RANDOM ALLOCATION; UNITED STATES;

EID: 0030600110     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0002-9343(96)00105-2     Document Type: Conference Paper

References (28)

1. Kessler RE, Fung-Tomc J. Susceptibility of bacterial isolates to β-lactam antibiotics from U.S. clinical trials over a 5-year period. Am J Med. 1996;100(suppl 6A):13S-19S.
2. Nikaido H, Liu W, Rosenberg EY. Outer membrane permeability and β-lactamase stability of dipolar ionic cephalosporins containing methoxyimino substituents. Antimicrob Agents Chemother. 1990;34:337-342.
3. Fung-Tomc J, Huczko E, Kolek B, et al. In vitro activities of cefepime alone and with amikacin against aminoglycoside-resistant gram-negative bacteria. Antimicrob Agents Chemother. 1991;35:2652-2654.
4. Giamarellou H, Sahin A, Chryssouli Z. Comparative in vitro evaluation of BMY-28142, a new broad-spectrum cephalosporin, versus other β-lactams against multiresistant gram-negative isolates. Drugs Exp Clin Res. 1987;13:149-153.
5. Uri JV, Burdash N, Bendas CM. The aminothiazol-oxyimino cephalosporin antibiotics with quaternary ammonium substituents at the 3-position. Acta Micobiologica Hungarica. 1988;35:327-356.
6. Yoshimura F, Nikaido H. Diffusion of β-lactam antibiotics through the porin channels of Escherichia coli K-12. Antimicrob Agents Chemother. 1985;27:84.
7. Bellido F, Pechère JC, Hancock REW. Novel method for measurement of outer membrane permeability to new β-lactams in intact Enterobacter cloacae cells. Antimicrob Agents Chemother. 1991;35:68-72.
8. Hancock REW, Bellido F. Factors involved in the enhanced efficacy against gram-negative bacteria of fourth generation cephalosporins. J Antimicrob Chemother. 1992;29(suppl A):1-6.
9. Fuchs PC, Jones RN, Barry AL, Thornsberry C. Evaluation of the in vitro activity of BMY-28142, a new broad-spectrum cephalosporin. Antimicrob Agents Chemother. 1985;27:679-682.
10. Pucci MJ, Boice-Sowek J, Kessler RE, Dougherty TJ. Comparison of cefepime, cefpirome, and cefaclidine binding affinities for penicillin-binding proteins in Escherichia coli K-12 and Pseudomonas aeruginosa SC8329. Antimicrob Agents Chemother. 1991;35:2312-2317.
11. Sanders CC. Cefepime: the next generation? Clin Infect Dis. 1993;17:369-379.
12. Jacoby GA, Carreras I. Activities of β-lactam antibiotics against Escherichia coli strains producing extended-spectrum β-lactamases. Antimicrob Agents Chemother. 1990;34:858-862.
13. Jones RN, Marshall SA. Antimicrobial activity of cefepime tested against Bush group 1 β-lactamase-producing strains resistant to ceftazidime. Diagn Microbial Infect Dis. 1994;19:33-38.
14. Bush K. Minireviews: characterization of β-lactamases. Antimicrob Agents Chemother. 1989;33:259-263.
15. Bush K. Classification of β-lactamases: groups 1, 2a, 2b, and 2b′. Antimicrob Agents Chemother. 1989;33:264-270.
16. Bush K. Classification of β-lactamases: groups 2c, 2d, 2e, 3, and 4. Antimicrob Agents Chemother. 1989;33:271-276.
17. Ballow CH, Schentag JJ. Trends in antibiotic utilization and bacterial resistance: report of the National Nosocomial Resistance Surveillance Group. Diagn Microbiol Infect Dis. 1992;15(suppl):37S-42S.
18. Masuyoshi S, Hiraoka M, Inoue M, et al. Comparison of the in vitro and in vivo antibacterial activities of cefepime (BMY-28142) with ceftazidime, cefuzonam, cefotaxime and cefmenoxime. Drugs Exp Clin Res. 1989;15:1-10.
19. Thornsberry C, Brown SD, Yee YE, et al. In vitro activity of cefepime and other antimicrobials: survey of European isolates. J Antimicrob Chemother. 1993;32(suppl B):31-53.
20. Washington JA, Jones RN, Gerlach EH, et al. Multicenter comparison of in vitro activities of FK-037, cefepime, ceftriaxone, ceftazidime, and cefuroxime. Antimicrob Agents Chemother. 1993;37:1696-1700.
21. Dyke JW, Angones D, Bhakta D, Tenjarla G, Kumar A. Antimicrobial activity of new antibiotics against bacterial isolates from a community hospital. Chemotherapy. 1993;39:315-321.
22. Liu YC, Huang WK, Cheng DL. Antibacterial activity of cefepime in vitro. Chemotherapy. 1994;40:384-390.
23. Chow JW, Fine MJ, Shlaes DM, et al. Enterobacter bacteremia: clinical features and emergence of antibiotic resistance during therapy. Ann Intern Med. 1991;115:585-590.
24. Schaberg DR, Culver DH, Gaynes RP. Major trends in the microbial etiology of nosocomial infection. Am J Med. 1991;91(suppl 3B):72S-75S.
25. Yee YC, Thornsberry C, Brown SD, Bouchillon SK, Marler JK, Rich T. A comparative study of the in-vitro activity of cefepime and other antimicrobial agents against penicillin-susceptible and penicillin-resistant Streptococcus pneumoniae. J Antimicrob Chemother. 1993;32(suppl B):13-19.
26. National Committee for Clinical Laboratory Standards. Method for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, 2nd ed. Approved Standard. NCCLS document M7-A2. NCCLS, Villanova, PA, 1990.
27. Baker CN, Stocker SA, Culver DH, et al. Comparison of the Etest®to agar dilution, broth microdilution, and agar diffusion susceptibility testing techniques by using a special challenge set of bacteria. J Clin Microbiol. 1991;29:533-538.
28. National Committee for Clinical Laboratory Standards. Performance Standards for Antimicrobial Disk Susceptibility Tests. NCCLS document M2-A4, 4th ed. 10(7). Villanova, PA, 1991.